Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ainos, Inc. - warrants
(NQ:
AIMDW
)
0.1548
-0.0030 (-1.90%)
Streaming Delayed Price
Updated: 11:28 AM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ainos, Inc. - warrants
< Previous
1
2
3
Next >
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
May 30, 2023
Via
ACCESSWIRE
Ainos Appoints Amanda Sung as New Chief Financial Officer
May 17, 2023
Via
ACCESSWIRE
Ainos Reports First Quarter 2023 Financial Results
May 12, 2023
Via
ACCESSWIRE
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
March 31, 2023
Via
ACCESSWIRE
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan
March 21, 2023
Via
ACCESSWIRE
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
March 14, 2023
Via
ACCESSWIRE
Ainos Announces US$3 Million Convertible Notes Private Placement
March 13, 2023
Via
ACCESSWIRE
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug
January 23, 2023
Via
ACCESSWIRE
Ainos Issues 2023 Shareholder Letter
January 17, 2023
Via
ACCESSWIRE
Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization
October 31, 2022
Via
ACCESSWIRE
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron
September 30, 2022
Via
ACCESSWIRE
Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms
August 24, 2022
Via
ACCESSWIRE
Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates
August 17, 2022
Via
ACCESSWIRE
Ainos Reports Second Quarter 2022 Financial Results
August 15, 2022
Via
ACCESSWIRE
Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
August 11, 2022
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.